NASDAQ: VTVT · Life Sciences · 2 alerts · CIK 1641489
Share price
$17.69Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All vTv Therapeutics Inc. filings on SEC EDGAR ↗
vTv Therapeutics reported a significantly reduced net loss of $0.5 million for the nine months ended September 30, 2026, compared to $23.9 million in the prior year, primarily due to $36.8 million in revenue recognized from contract liabilities. However, the company experienced an operating loss of $12.4 million for the third quarter as research and development expenses increased to support ongoing clinical programs.
vTv Therapeutics reported third quarter 2026 financial results and provided a corporate update, highlighting the completion of enrollment for its Phase 3 CATT1 trial of cadisegliatin in type 1 diabetes. The company also announced that the FDA granted Orphan Drug Designation to HPPD for sickle cell disease and expects its current cash position to fund operations through the mid-2027 CATT1 topline data readout.
“Completing enrollment in the Phase 3 CATT1 trial is a significant milestone for vTv, and we look forward to reporting topline results in mid 2027.”
Paul Sekhri, Chairman, President and Chief Executive Officer
“The FDA recently granted Orphan Drug Designation for HPPD, which has shown promising activity in preclinical models of sickle cell disease. This designation strengthens our ability to advance partnering discussions for this program and provides another opportunity to create value for shareholders.”
Paul Sekhri, Chairman, President and Chief Executive Officer